Merus Labs International Inc (MSL) PT Lowered to C$1.60
Merus Labs International Inc (TSE:MSL) had its price objective lowered by investment analysts at Paradigm Capital from C$1.75 to C$1.60 in a report issued on Tuesday. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. Paradigm Capital’s price target would suggest a potential upside of 20.30% from the stock’s previous close.
Other equities research analysts have also issued research reports about the company. Scotiabank reduced their price objective on Merus Labs International from C$2.25 to C$1.75 and set a “sector perform” rating on the stock in a research report on Tuesday, August 16th. TD Securities restated a “buy” rating and set a C$4.00 price objective on shares of Merus Labs International in a research report on Tuesday, August 16th. CIBC reduced their price objective on Merus Labs International from C$2.90 to C$2.50 in a research report on Tuesday, August 16th. Finally, Canaccord Genuity reduced their price objective on Merus Labs International from C$4.25 to C$3.50 and set a “buy” rating on the stock in a research report on Tuesday, August 16th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of C$2.77.
Merus Labs International (TSE:MSL) traded down 0.75% during midday trading on Tuesday, hitting $1.32. The stock had a trading volume of 70,300 shares. Merus Labs International has a 52 week low of $1.18 and a 52 week high of $2.40. The company’s 50 day moving average price is $1.32 and its 200-day moving average price is $1.65. The stock’s market capitalization is $154.44 million.
About Merus Labs International
Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.
Receive News & Stock Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related stocks with our FREE daily email newsletter.